Tiemann Investment Advisors LLC Takes $258,000 Position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Tiemann Investment Advisors LLC acquired a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 6,962 shares of the company’s stock, valued at approximately $258,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Asset Management One Co. Ltd. bought a new position in Amphastar Pharmaceuticals during the third quarter worth about $78,000. Assetmark Inc. raised its position in shares of Amphastar Pharmaceuticals by 9.1% in the 3rd quarter. Assetmark Inc. now owns 43,906 shares of the company’s stock valued at $2,131,000 after acquiring an additional 3,650 shares during the period. Los Angeles Capital Management LLC bought a new position in Amphastar Pharmaceuticals during the 3rd quarter worth approximately $785,000. GSA Capital Partners LLP acquired a new position in Amphastar Pharmaceuticals during the third quarter valued at approximately $303,000. Finally, Victory Capital Management Inc. increased its stake in Amphastar Pharmaceuticals by 10.9% in the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company’s stock valued at $10,605,000 after purchasing an additional 21,530 shares in the last quarter. Institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

Shares of AMPH opened at $28.81 on Monday. The firm has a market cap of $1.37 billion, a P/E ratio of 9.60, a PEG ratio of 2.19 and a beta of 0.77. Amphastar Pharmaceuticals, Inc. has a twelve month low of $26.98 and a twelve month high of $53.96. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. The firm’s 50 day moving average price is $33.71 and its two-hundred day moving average price is $41.93.

Insider Buying and Selling

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total value of $116,521.74. Following the sale, the chief financial officer now owns 97,363 shares of the company’s stock, valued at $2,681,377.02. This trade represents a 4.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Rong Zhou sold 7,000 shares of the company’s stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $44.42, for a total value of $310,940.00. Following the transaction, the executive vice president now directly owns 118,469 shares of the company’s stock, valued at $5,262,392.98. This represents a 5.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 27.10% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on AMPH. Wells Fargo & Company started coverage on shares of Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They set an “equal weight” rating and a $55.00 price target on the stock. Piper Sandler downgraded Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $66.00 to $36.00 in a research note on Tuesday, February 4th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.